Blood Test Aids in Identifying Treatment Resistance in Metastatic Breast Cancer

Share this content:
A new sensitized blood test can help clinicians discover when breast cancers become resistant to standard hormone therapy.
A new sensitized blood test can help clinicians discover when breast cancers become resistant to standard hormone therapy.

A new sensitized blood test can help clinicians discover when breast cancers become resistant to standard hormone therapy.1

Results from one study showed that blood sample analyses that tested the circulating tumor DNA (ctDNA) could provide early warning for mutations to the estrogen receptor gene ESR1, which serves as an indicator that resistance to aromatase inhibitors is occurring. Aromatase inhibitors block or suppress estrogen, however mutations in the ESR1 gene can help tumors evade and resist these hormone therapies.

Dr. Lajos Pusztai, MD, DPhil, of Yale Cancer Center in New Haven, CT, who was not affiliated with the study, told Cancer Therapy Advisor  that the novelty of the study's findings is that the use of a blood assay helps clinicians use a less invasive method than tissue analysis to identify patients with mutations.

RELATED: Internal Mammary Node Irradiation Improves Survival in Early Node+ Breast Cancer

Dr. Nicholas Turner, MD, team leader in molecular oncology at The Institute of Cancer Research in London, United Kingdom, said in a statement sent by the institute “The test could give doctors an early warning of treatment failure and, as clinical trials of drugs that target ESR1 mutations are developed, help select the most appropriate treatment for women with advanced cancer.”

Ultra-sensitive Blood Test

In the study, Gaia Schiavon and researchers from The Institute of Cancer Research and The Royal Marsden Hospital, both in London, United Kingdom, took blood samples from 171 women with advanced estrogen receptor (ER)-positive breast cancer to find ESR1 mutations. Of those who were given aromatase therapy, none had an ESR1 mutation prior to starting treatment.

They then validated the results in 3 independent groups of patients.

Page 1 of 2

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters